- Home
- KWE vs GLMD Comparison
KWE vs GLMD Comparison
Compare KWE & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KWE
- GLMD
- Stock Information
- Founded
- KWE 2017
- GLMD 2000
- Country
- KWE Canada
- GLMD Israel
- Employees
- KWE N/A
- GLMD N/A
- Industry
- KWE
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- KWE
- GLMD Health Care
- Exchange
- KWE Nasdaq
- GLMD Nasdaq
- Market Cap
- KWE 4.5M
- GLMD 4.5M
- IPO Year
- KWE N/A
- GLMD 2014
- Fundamental
- Price
- KWE $0.47
- GLMD $2.69
- Analyst Decision
- KWE
- GLMD
- Analyst Count
- KWE 0
- GLMD 0
- Target Price
- KWE N/A
- GLMD N/A
- AVG Volume (30 Days)
- KWE 1.2M
- GLMD 25.9K
- Earning Date
- KWE 12-30-2024
- GLMD 11-14-2024
- Dividend Yield
- KWE N/A
- GLMD N/A
- EPS Growth
- KWE N/A
- GLMD N/A
- EPS
- KWE N/A
- GLMD N/A
- Revenue
- KWE $1,113,533.00
- GLMD N/A
- Revenue This Year
- KWE N/A
- GLMD N/A
- Revenue Next Year
- KWE N/A
- GLMD N/A
- P/E Ratio
- KWE N/A
- GLMD N/A
- Revenue Growth
- KWE 21.86
- GLMD N/A
- 52 Week Low
- KWE $0.43
- GLMD $2.56
- 52 Week High
- KWE $14.90
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- KWE 38.06
- GLMD 37.61
- Support Level
- KWE $0.48
- GLMD $2.66
- Resistance Level
- KWE $0.54
- GLMD $3.45
- Average True Range (ATR)
- KWE 0.05
- GLMD 0.18
- MACD
- KWE -0.01
- GLMD -0.02
- Stochastic Oscillator
- KWE 31.82
- GLMD 0.61
About KWE KWESST Micro Systems Inc.
KWESST Micro Systems Inc develops and commercializes next-generation tactical systems. The company offers breakthrough technology in lethal and non-lethal systems with broad application, including law enforcement and personal defence, modernized digitization of tactical forces for shared situational awareness and targeting, and counter-measures against threats such as drones, lasers and electronic detection.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.